Sydney-based Pharmaxis (ASX:PXS) has announced the first patient has been dosed in its Phase 1 clinical trial of an anti‐fibrotic Lysyl Oxidase (LOX) inhibitor focused on treating pancreatic cancer. …
Latest Video
New Stories
-
New details confirm pre-election rush to approve CAR-T
April 23, 2019 - - Latest News -
MSAC: 'Strategic decisions' needed with emerging gene therapies
April 23, 2019 - - Latest News -
Is that really funding early access to treatment?
April 23, 2019 - - Latest News -
Researchers propose biosimilar price regulation over uptake
April 23, 2019 - - Latest News -
PEFO confirms MA secured ATAGI fee delay
April 18, 2019 - - Latest News -
'Right to Trial' in blood cancers-a limited version of Trump's 'Right to Try'
April 18, 2019 - - Latest News -
MA starts communication on 'principles' Code
April 18, 2019 - - Latest News